Skip to main content

Latest news

Thu, 04/05/2018 - 09:00
  • ELSALYS BIOTECH plans to submit to the European Medicines Agency before summer 2018 a Paediatric Investigation Plan (PIP) proposing to c

Thu, 03/15/2018 - 17:00
  • A poster summarising the safety profile results of the randomised Phase 3 testing LEUKOTAC® in patients with steroid-resistant acute gra

Thu, 02/22/2018 - 17:00
  • ELB011, a first-in-class antibody program, demonstrates an anti-angiogenic effect on the formation of new blood vessels which cause cert

Thu, 10/12/2017 - 17:00
  • In a recent clinical study, it has shown a - favorable risk/benefit profile, supporting the experience already obtained with LEUKOTAC® i

Tue, 07/18/2017 - 17:00
  • With the support of the EU program Eurostar*, ELSALYS BIOTECH & DKFZ initiate the preclinical development of this next-generation im

Mon, 01/30/2017 - 17:00

After having recently enriched its pipeline of therapeutic antibodies in oncology, ElsaLys Biotech strengthens its management team with the arriva

Thu, 12/15/2016 - 17:00
  • Initially developed by TRANSGENE, one of ELSALYS BIOTECH’s founding shareholders, this antibody inhibits a deleterious subpopulation of

Tue, 02/16/2016 - 17:00
  • Having acquired in June 2015 the assets of CD160 in the field of ophthalmology, ElsaLys Biotech strengthens its intellectual property an

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter